thalidomide has been researched along with Erythema Nodosum in 148 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Erythema Nodosum: An erythematous eruption commonly associated with drug reactions or infection and characterized by inflammatory nodules that are usually tender, multiple, and bilateral. These nodules are located predominantly on the shins with less common occurrence on the thighs and forearms. They undergo characteristic color changes ending in temporary bruise-like areas. This condition usually subsides in 3-6 weeks without scarring or atrophy.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In a randomized, double-blind, double-dummy controlled study, 22 men with erythema nodosum leprosum (ENL) received six capsules containing either 100 mg (group A, n = 12) or 300 mg (group B, n = 10) of thalidomide daily for one week." | 9.11 | A randomized, double-blind, double-dummy, controlled dose comparison of thalidomide for treatment of erythema nodosum leprosum. ( Abalos, RM; Balagon, MV; Cellona, RV; Fajardo, TT; Kook, KA; Palmer, JP; Tan, EV; Thomas, SD; Villahermosa, LG; Walsh, DS; Walsh, GP; Wittes, J, 2005) |
| "Treatment of erythema nodosum leprosum (ENL, type 2 reaction) using thalidomide provides effective alternative choice to steroid therapy." | 8.87 | [Japanese guideline on thalidomide usage in the management of erythema nodosum leprosum]. ( Gidoh, M; Goto, M; Hatano, K; Ishida, Y; Ishii, N; Kumano, K; Nogami, R; Okano, Y; Ozaki, M; Yamada, A; Yotsu, RR, 2011) |
| "Thalidomide is being successfully used for the treatment of erythema nodosum leprosum (ENL), among other disorders with inflammatory and immunological bases." | 8.81 | Management of erythema nodosum leprosum by thalidomide: thalidomide analogues inhibit M. leprae-induced TNFalpha production in vitro. ( Carvalho, DS; Hernandez, MO; Sampaio, EP; Sarno, EN, 2002) |
| "Thalidomide is an immunomodulatory drug and first choice in the treatment of erythema nodosum leprosum." | 8.12 | Etonogestrel-releasing contraceptive implant in a patient using thalidomide for the treatment of erythema nodosum leprosum: a case report. ( Bahamondes, L; Baracat, EC; de Almeida, PG; Duarte, DC; Ferreira-Filho, ES; Guimarães, ALM; Soares-Júnior, JM; Sorpreso, ICE, 2022) |
| "Thalidomide is an anti- tumor necrosis factor alpha (TNF-a) drug used mainly in the management of moderate to severe form of Erythema Nodosum Leprosum (ENL)." | 7.96 | Rationale use of Thalidomide in erythema nodosum leprosum - A non-systematic critical analysis of published case reports. ( Babu, S; Gurunthalingam, M; T, T; Thangaraju, P; Venkatesan, S, 2020) |
| "Thalidomide is well known as a steroid sparing drug in Erythema Nodosum leprosum (ENL) reaction in leprosy." | 7.83 | Experiences with Thalidomide for Erythema Nodosum Leprosum– a retrospective study. ( Charles, DE; Darlong, J; Govindharaj, P; Mani, S; Menzies, A, 2016) |
| "Thalidomide is a TNF-alpha inhibitor and has been administrated for erythema nodosum leprosum (ENL, Type II leprosy reaction) which is one of leprosy reactions and can cause serious illness to patients oflepromatous pole among the immune spectrum." | 7.80 | [Effectiveness of thalidomide for erythema nodosum leprosum (ENL): retrospective study of 20 Japanese cases in National Sanatrium Oku-Komyoen]. ( Aoki, Y; Hatano, K; Ishida, Y; Kumano, K; Matsuki, T; Okano, Y, 2014) |
| "Thalidomide is used for the acute treatment and suppression of the cutaneous manifestations of erythema nodosum leprosum (ENL)." | 7.75 | Thalidomide levels in patients with erythema nodosum leprosum. ( Valente, Mdo S; Vieira, JL, 2009) |
| "Thalidomide is the drug of choice in the treatment of severe erythema nodosum leprosum (ENL) in men." | 7.74 | A case report of venous thrombosis in a leprosy patient treated with corticosteroid and thalidomide. ( Pise, GA; Thappa, DM; Vetrichevvel, TP, 2008) |
| "The immunomodulatory drug thalidomide is the treatment of choice for erythema nodosum leprosum (ENL), an inflammatory cutaneous and systemic complication of multibacillary leprosy." | 7.73 | Effective treatment of erythema nodosum leprosum with thalidomide is associated with immune stimulation. ( Albert, M; Butlin, CR; Haslett, PA; Hawksworth, R; Kaplan, G; Lemaster, J; Lubinsky, AS; Macdonald, M; Manandhar, R; Roche, P; Shah, M; Shrestha, N; Worley, J, 2005) |
| "Thalidomide is well documented as being an effective drug in the treatment of erythema nodosum leprosum (ENL)." | 7.68 | Thalidomide's effectiveness in erythema nodosum leprosum is associated with a decrease in CD4+ cells in the peripheral blood. ( Berhan, TY; Ejigu, M; Haile-Mariam, HS; Shannon, EJ; Tasesse, G, 1992) |
| "Immunologic and clinical manifestations of erythema nodosum leprosum (ENL) and their response to thalidomide therapy were evaluated." | 7.68 | The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum. ( Kaplan, G; Miguel, CP; Miranda, A; Nery, JA; Sampaio, EP; Sarno, EN; Viana, SM, 1993) |
| "Thalidomide is well documented to be an effective treatment for erythema nodosum leprosum (ENL) occurring in lepromatous leprosy." | 7.66 | Inhibition of de novo IgM antibody synthesis by thalidomide as a relevant mechanism of action in leprosy. ( Hastings, RC; Miranda, RO; Morales, MJ; Shannon, EJ, 1981) |
| " The patients received PTX at the initiating dosage until complete clinical cure." | 6.71 | [Pentoxifylline in the treatment of erythema nodosum leprosum: results of an open study]. ( Achirafi, A; de Carsalade, GY; Flageul, B, 2003) |
| "40 000 new cases of leprosy are diagnosed every year in Brazil." | 6.49 | Recognition of the phenotype of thalidomide embryopathy in countries endemic for leprosy: new cases and review of the main dysmorphological findings. ( da Costa, LMM; de Sousa, SHC; Dias, MF; Doriqui, MJR; Leite, JCL; Maximino, CM; Morelo, EF; Sanseverino, MTV; Schüler-Faccini, L; Vianna, FSL, 2013) |
| "Treatment with thalidomide provides an effective alternative to steroid therapy, gives better long-term control and avoids the adverse effects of prolonged steroid therapy." | 6.44 | The role of thalidomide in the management of erythema nodosum leprosum. ( Lockwood, DN; Walker, SL; Waters, MF, 2007) |
| "reported that the bone marrow of multiple myeloma (MM) patients was rich in blood vessels and that there is a causal relationship between the activity of MM and marrow angiogenesis." | 6.42 | [New pharmacological availability of thalidomide based on experience in patients with multiple myeloma]. ( Murakami, H, 2004) |
| "Thalidomide has been used to treat ENL since the 1960s." | 6.41 | Thalidomide in the treatment of leprosy. ( Kook, KA; Resztak, KE; Scheffler, MA; Stirling, DI; Teo, S; Thomas, SD; Zeldis, JB, 2002) |
| "Thalidomide is an immunomodulatory and anti-inflammatory drug currently used to treat this condition." | 5.72 | Evaluation of the influence of genetic variants in Cereblon gene on the response to the treatment of erythema nodosum leprosum with thalidomide. ( Caldoncelli, DIO; Camargo, LMA; Costa, PDSS; Feira, MF; Fraga, LR; Kowalski, TW; Maciel-Fiuza, MF; Schuler-Faccini, L; Silveira, MIDS; Vianna, FSL, 2022) |
| "Thalidomide has proven to be a steroid-sparing agent and is useful in controlling the reactions." | 5.56 | Thalidomide in the treatment of erythema nodosum leprosum (ENL) in an outpatient setting: A five-year retrospective analysis from a leprosy referral centre in India. ( Pallapati, MS; Srikantam, A; Tarwater, P; Upputuri, B, 2020) |
| "Apremilast is an orally effective phosphodiesterase-4 inhibitor with a potent immunomodulatory action and is clinically effective in inflammatory conditions like chronic plaque psoriasis." | 5.56 | Apremilast in chronic recalcitrant erythema nodosum leprosum: a report of two cases. ( Dogra, S; Kaushik, A; Narang, T, 2020) |
| "Erythema nodosum (EN) is a panniculitis frequently encountered secondary to medical therapy." | 5.43 | Erythema Nodosum-like Septal Panniculitis Secondary to Lenalidomide Therapy in a Patient With Janus Kinase 2-Positive Myelofibrosis. ( Fung, MA; Jagdeo, J; Mayo, K; Petukhova, TA; Tartar, DM; Tuscano, J, 2016) |
| "Thalidomide has been proven to be helpful and averted the adverse effects from systemic corticosteroids and other immunosuppressive drugs in this patient." | 5.38 | Propylthiouracil-induced ANCA-positive erythema nodosum treated with thalidomide. ( Hunasehally, RY; Shi, R; Wan, P; Zhao, X; Zheng, J, 2012) |
| "Thalidomide is an effective treatment for ENL but not RR." | 5.33 | Effect of thalidomide on the expression of TNF-alpha m-RNA and synthesis of TNF-alpha in cells from leprosy patients with reversal reaction. ( Abebe, M; Aseffa, A; Bizuneh, E; Mulugeta, W; Shannon, EJ; Tadesse, A, 2006) |
| "But eventually due to recurrence these cases had to be put back on steroids because of easier availability." | 5.26 | Treatment with thalidomide in steroid dependency and neuritis. ( Theophilus, S, 1980) |
| "The US FDA-approved thalidomide for the treatment of chronic recurrent/severe erythema nodosum leprosum." | 5.12 | Thalidomide: an experience in therapeutic outcome and adverse reactions. ( Gupta, M; Mahajan, VK; Ranjan, N; Shanker, V; Sharma, NL; Sharma, VC, 2007) |
| "In a randomized, double-blind, double-dummy controlled study, 22 men with erythema nodosum leprosum (ENL) received six capsules containing either 100 mg (group A, n = 12) or 300 mg (group B, n = 10) of thalidomide daily for one week." | 5.11 | A randomized, double-blind, double-dummy, controlled dose comparison of thalidomide for treatment of erythema nodosum leprosum. ( Abalos, RM; Balagon, MV; Cellona, RV; Fajardo, TT; Kook, KA; Palmer, JP; Tan, EV; Thomas, SD; Villahermosa, LG; Walsh, DS; Walsh, GP; Wittes, J, 2005) |
| "A group of 9 Mexican lepromatous leprosy patients was studied at the beginning of a type II reaction (erythema nodosum leprosum, ENL) and after 1 or 2 months of thalidomide treatment." | 5.08 | IgG antibody subclasses, tumor necrosis factor and IFN-gamma levels in patients with type II lepra reaction on thalidomide treatment. ( Estrada-Garcia, I; Estrada-Parra, S; Favila-Castillo, L; Gomez-Melgar, M; Partida-Sanchez, S; Pedraza-Sanchez, S; Saul, A, 1998) |
| "We report a patient with severe multi-bacillary leprosy complicated by recurrent episodes of erythema nodosum necrotisans that required thalidomide and/or corticosteroids during follow-up." | 4.87 | A patient with erythema nodosus leprosum and Chagas cardiopathy: challenges in patient management and review of the literature. ( Belfort, EC; Benard, G; Carvalho, NB; Gakiya, E; Pagliari, C; Sakai-Valente, NY; Shikanai-Yasuda, MA; Trindade, MÂ, 2011) |
| "Treatment of erythema nodosum leprosum (ENL, type 2 reaction) using thalidomide provides effective alternative choice to steroid therapy." | 4.87 | [Japanese guideline on thalidomide usage in the management of erythema nodosum leprosum]. ( Gidoh, M; Goto, M; Hatano, K; Ishida, Y; Ishii, N; Kumano, K; Nogami, R; Okano, Y; Ozaki, M; Yamada, A; Yotsu, RR, 2011) |
| " We report a case of deep venous thrombosis (DVT) and pulmonary embolus (PE) following thalidomide use in a patient with leprosy (erythema nodosum leprosum, ENL) who was concurrently treated with prednisone, as well as a review of relevant literature." | 4.85 | Frequency of thromboembolic events associated with thalidomide in the non-cancer setting: a case report and review of the literature. ( Boone, SL; Fabi, SG; Hill, C; West, DP; Witherspoon, JN, 2009) |
| "A 37-year-old female patient experienced oral ulcer and erythema nodosum on the right leg for over 12 months and resisted to Methylprednisolone and Thalidomide." | 4.12 | Refractory Behçet's disease treated with low-dose interleukin-2: A case report. ( He, J; Liu, T; Xiao, X; Zhou, W, 2022) |
| "Thalidomide is an immunomodulatory drug and first choice in the treatment of erythema nodosum leprosum." | 4.12 | Etonogestrel-releasing contraceptive implant in a patient using thalidomide for the treatment of erythema nodosum leprosum: a case report. ( Bahamondes, L; Baracat, EC; de Almeida, PG; Duarte, DC; Ferreira-Filho, ES; Guimarães, ALM; Soares-Júnior, JM; Sorpreso, ICE, 2022) |
| "Thalidomide is an anti- tumor necrosis factor alpha (TNF-a) drug used mainly in the management of moderate to severe form of Erythema Nodosum Leprosum (ENL)." | 3.96 | Rationale use of Thalidomide in erythema nodosum leprosum - A non-systematic critical analysis of published case reports. ( Babu, S; Gurunthalingam, M; T, T; Thangaraju, P; Venkatesan, S, 2020) |
| "Thalidomide is well known as a steroid sparing drug in Erythema Nodosum leprosum (ENL) reaction in leprosy." | 3.83 | Experiences with Thalidomide for Erythema Nodosum Leprosum– a retrospective study. ( Charles, DE; Darlong, J; Govindharaj, P; Mani, S; Menzies, A, 2016) |
| "Thalidomide is a TNF-alpha inhibitor and has been administrated for erythema nodosum leprosum (ENL, Type II leprosy reaction) which is one of leprosy reactions and can cause serious illness to patients oflepromatous pole among the immune spectrum." | 3.80 | [Effectiveness of thalidomide for erythema nodosum leprosum (ENL): retrospective study of 20 Japanese cases in National Sanatrium Oku-Komyoen]. ( Aoki, Y; Hatano, K; Ishida, Y; Kumano, K; Matsuki, T; Okano, Y, 2014) |
| "In the present study, we set out to explore the T helper 17 (TH17) lymphocyte subset, the hallmark of T-cell plasticity, in skin biopsies from patients with erythema nodosum leprosum (ENL) who were treated with thalidomide." | 3.78 | Lessons of leprosy: the emergence of TH17 cytokines during type II reactions (ENL) is teaching us about T-cell plasticity. ( Giovinazzo, J; Haslett, P; Kaplan, G; Levis, WR; Martiniuk, F; Shahidullah, R; Tan, AU, 2012) |
| "Erythema nodosum leprosum (ENL) is an inflammatory reaction that may occur in multibacillary leprosy patients, and thalidomide is the treatment of choice." | 3.77 | In vitro thalidomide does not interfere with the activation of complement by M. leprae. ( Morales, MJ; Sandoval, FG; Shannon, EJ, 2011) |
| "Thalidomide is used for the acute treatment and suppression of the cutaneous manifestations of erythema nodosum leprosum (ENL)." | 3.75 | Thalidomide levels in patients with erythema nodosum leprosum. ( Valente, Mdo S; Vieira, JL, 2009) |
| "Thalidomide is the drug of choice in the treatment of severe erythema nodosum leprosum (ENL) in men." | 3.74 | A case report of venous thrombosis in a leprosy patient treated with corticosteroid and thalidomide. ( Pise, GA; Thappa, DM; Vetrichevvel, TP, 2008) |
| "The immunomodulatory drug thalidomide is the treatment of choice for erythema nodosum leprosum (ENL), an inflammatory cutaneous and systemic complication of multibacillary leprosy." | 3.73 | Effective treatment of erythema nodosum leprosum with thalidomide is associated with immune stimulation. ( Albert, M; Butlin, CR; Haslett, PA; Hawksworth, R; Kaplan, G; Lemaster, J; Lubinsky, AS; Macdonald, M; Manandhar, R; Roche, P; Shah, M; Shrestha, N; Worley, J, 2005) |
| "Changes in hemoglobin (HGB) and serum albumin (SA) concentration associated with the onset of symptomatic erythema nodosum leprosum (ENL) were studied by comparing the values obtained on the day thalidomide or prednisone therapy commenced, with each patients' preceding values." | 3.71 | Decreases in mean hemoglobin and serum albumin values in erythema nodosum leprosum and lepromatous leprosy. ( Rea, TH, 2001) |
| "Changes in peripheral blood platelet counts associated with the onset of symptomatic erythema nodosum leprosum (ENL) were studied by comparing, in each patient, the value obtained on the day thalidomide therapy commenced with the average of the three preceding values." | 3.71 | Elevated platelet counts and thrombocytosis in erythema nodosum leprosum. ( Rea, TH, 2002) |
| "Immunologic and clinical manifestations of erythema nodosum leprosum (ENL) and their response to thalidomide therapy were evaluated." | 3.68 | The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum. ( Kaplan, G; Miguel, CP; Miranda, A; Nery, JA; Sampaio, EP; Sarno, EN; Viana, SM, 1993) |
| "Thalidomide is well documented as being an effective drug in the treatment of erythema nodosum leprosum (ENL)." | 3.68 | Thalidomide's effectiveness in erythema nodosum leprosum is associated with a decrease in CD4+ cells in the peripheral blood. ( Berhan, TY; Ejigu, M; Haile-Mariam, HS; Shannon, EJ; Tasesse, G, 1992) |
| "Thalidomide is the drug of choice in the erythema nodosum leprosum (ENL) type of lepra reaction." | 3.67 | Thalidomide--effect on T cell subsets as a possible mechanism of action. ( Baranda, ML; González-Amaro, R; Loredo, CE; Moncada, B; Urbina, R, 1985) |
| " Lucio's phenomenon is a syndrome distinct from erythema nodosum leprosum as indicated by an absence of fever, leukocytosis and tenderness, a failure to respond to thalidomide, and a restriction to patients with diffuse nonnodular lepromatous leprosy." | 3.66 | Lucio's phenomenon and diffuse nonnodular lepromatous leprosy. ( Levan, NE; Rea, TH, 1978) |
| "Thalidomide is well documented to be an effective treatment for erythema nodosum leprosum (ENL) occurring in lepromatous leprosy." | 3.66 | Inhibition of de novo IgM antibody synthesis by thalidomide as a relevant mechanism of action in leprosy. ( Hastings, RC; Miranda, RO; Morales, MJ; Shannon, EJ, 1981) |
| " Reactive episodes continue to be a serious complication, but the availability of thalidomide to control erythema nodosum leprosum has markedly improved the prognosis." | 3.65 | The diagnosis and treatment of leprosy. ( Jacobson, RR; Trautman, JR, 1976) |
| "This analysis allows us to think beyond the safe use of thalidomide, but the safety provided by any type of monitoring system." | 2.82 | Comparative analysis of the use and control of thalidomide in Brazil and different countries: is it possible to say there is safety? ( de Jesus, SM; Leite, SN; Santana, RS, 2022) |
| "Thalidomide has been shown to be a highly effective drug for the treatment of ENL." | 2.73 | Double-blind trial of the efficacy of pentoxifylline vs thalidomide for the treatment of type II reaction in leprosy. ( de Matos, HJ; Duppre, NC; Nery, JA; Sales, AM; Sampaio, EP; Sarno, EN, 2007) |
| " The patients received PTX at the initiating dosage until complete clinical cure." | 2.71 | [Pentoxifylline in the treatment of erythema nodosum leprosum: results of an open study]. ( Achirafi, A; de Carsalade, GY; Flageul, B, 2003) |
| "Thalidomide has a rapid action but its use is limited due the teratogenicity and neurotoxicity." | 2.58 | Erythema Nodosum Leprosum: Update and challenges on the treatment of a neglected condition. ( Costa, PDSS; Daxbacher, ELR; Fraga, LR; Kowalski, TW; Schuler-Faccini, L; Vianna, FSL, 2018) |
| "40 000 new cases of leprosy are diagnosed every year in Brazil." | 2.49 | Recognition of the phenotype of thalidomide embryopathy in countries endemic for leprosy: new cases and review of the main dysmorphological findings. ( da Costa, LMM; de Sousa, SHC; Dias, MF; Doriqui, MJR; Leite, JCL; Maximino, CM; Morelo, EF; Sanseverino, MTV; Schüler-Faccini, L; Vianna, FSL, 2013) |
| "Food and Drug Administation for treatment of erythema nodosum in leprosy and is now approved for multiple myeloma as well." | 2.46 | Thalidomide and analogues: potential for immunomodulation of inflammatory and neoplastic dermatologic disorders. ( Ladizinski, B; Levis, WR; Sanchez, MR; Shannon, EJ, 2010) |
| "Treatment with thalidomide showed a significant benefit compared to aspirin (RR 2." | 2.45 | Interventions for erythema nodosum leprosum. A Cochrane review. ( Lockwood, DN; Ramirez, J; Richardus, JH; Van Brakel, WH; Van Veen, NH, 2009) |
| "Clofazimine treatment was superior to prednisolone (more treatment successes; RR 3." | 2.45 | Interventions for erythema nodosum leprosum. ( Lockwood, DN; Ramirez, J; Richardus, JH; van Brakel, WH; Van Veen, NH, 2009) |
| "Treatment with thalidomide provides an effective alternative to steroid therapy, gives better long-term control and avoids the adverse effects of prolonged steroid therapy." | 2.44 | The role of thalidomide in the management of erythema nodosum leprosum. ( Lockwood, DN; Walker, SL; Waters, MF, 2007) |
| "To review the history of the treatment of leprosy and leprosy reactions after World War II." | 2.43 | Treatment of leprosy: science or politics? ( Naafs, B, 2006) |
| "Thalidomide was first used in the late 1950s but it was withdrawn from the market in the 1960s for its notorious teratogenic effects." | 2.42 | The promise of thalidomide: evolving indications. ( Joglekar, S; Levin, M, 2004) |
| "reported that the bone marrow of multiple myeloma (MM) patients was rich in blood vessels and that there is a causal relationship between the activity of MM and marrow angiogenesis." | 2.42 | [New pharmacological availability of thalidomide based on experience in patients with multiple myeloma]. ( Murakami, H, 2004) |
| "Thalidomide has been used to treat ENL since the 1960s." | 2.41 | Thalidomide in the treatment of leprosy. ( Kook, KA; Resztak, KE; Scheffler, MA; Stirling, DI; Teo, S; Thomas, SD; Zeldis, JB, 2002) |
| "Thalidomide was withdrawn from the market in the early sixties because of its teratogenic effects." | 2.41 | [Thalidomide: new uses for an old drug]. ( Sonneveld, P; Wu, KL, 2002) |
| "Thalidomide was later found to very effectively suppress erythema nodosum leprosum (ENL)." | 2.41 | Thalomid (Thalidomide) capsules: a review of the first 18 months of spontaneous postmarketing adverse event surveillance, including off-label prescribing. ( Clark, TE; Edom, N; Larson, J; Lindsey, LJ, 2001) |
| "Thalidomide is an immunomodulatory and anti-inflammatory drug currently used to treat this condition." | 1.72 | Evaluation of the influence of genetic variants in Cereblon gene on the response to the treatment of erythema nodosum leprosum with thalidomide. ( Caldoncelli, DIO; Camargo, LMA; Costa, PDSS; Feira, MF; Fraga, LR; Kowalski, TW; Maciel-Fiuza, MF; Schuler-Faccini, L; Silveira, MIDS; Vianna, FSL, 2022) |
| "Apremilast is an orally effective phosphodiesterase-4 inhibitor with a potent immunomodulatory action and is clinically effective in inflammatory conditions like chronic plaque psoriasis." | 1.56 | Apremilast in chronic recalcitrant erythema nodosum leprosum: a report of two cases. ( Dogra, S; Kaushik, A; Narang, T, 2020) |
| "Thalidomide has proven to be a steroid-sparing agent and is useful in controlling the reactions." | 1.56 | Thalidomide in the treatment of erythema nodosum leprosum (ENL) in an outpatient setting: A five-year retrospective analysis from a leprosy referral centre in India. ( Pallapati, MS; Srikantam, A; Tarwater, P; Upputuri, B, 2020) |
| "Thalidomide treatment reduced PTX3 in the serum 7 days after starting treatment." | 1.46 | Elevated Pentraxin-3 Concentrations in Patients With Leprosy: Potential Biomarker of Erythema Nodosum Leprosum. ( Amadeu, TP; da Silva, CO; de Carvalho, DS; Ferreira, H; Hacker, MA; Mendes, MA; Nery, JAC; Pinheiro, RO; Prata, RBDS; Sampaio, EP; Sarno, EN; Schmitz, V; Silva, BJA, 2017) |
| "Erythema nodosum (EN) is a panniculitis frequently encountered secondary to medical therapy." | 1.43 | Erythema Nodosum-like Septal Panniculitis Secondary to Lenalidomide Therapy in a Patient With Janus Kinase 2-Positive Myelofibrosis. ( Fung, MA; Jagdeo, J; Mayo, K; Petukhova, TA; Tartar, DM; Tuscano, J, 2016) |
| "Thalidomide treatment is extremely effective at ameliorating ENL symptoms." | 1.43 | Expression of CD64 on Circulating Neutrophils Favoring Systemic Inflammatory Status in Erythema Nodosum Leprosum. ( Amadeu, TP; Barbosa, MG; Brandão, SS; Costa, Fda M; Dos Santos, JB; Ferreira, H; Hacker, Mde A; Machado, Ade M; Mendes, MA; Nery, JA; Pacheco, Fdos S; Pinheiro, RO; Prata, RB; Rodrigues, LS; Sales, AM; Sarno, EN; Schmitz, V, 2016) |
| "Type 2 lepra reaction is a Th2-mediated type III hypersensitivity reaction in leprosy, with a characteristic cutaneous manifestation in the form of erythema nodosum leprosum (ENL)." | 1.40 | Rare atypical presentations in Type 2 lepra reaction: a case series. ( Badad, A; Mitra, D; Neema, S; Vasudevan, B; Verma, R; Vijendran, P, 2014) |
| "Thalidomide has been proven to be helpful and averted the adverse effects from systemic corticosteroids and other immunosuppressive drugs in this patient." | 1.38 | Propylthiouracil-induced ANCA-positive erythema nodosum treated with thalidomide. ( Hunasehally, RY; Shi, R; Wan, P; Zhao, X; Zheng, J, 2012) |
| "Thalidomide is an effective treatment for ENL but not RR." | 1.33 | Effect of thalidomide on the expression of TNF-alpha m-RNA and synthesis of TNF-alpha in cells from leprosy patients with reversal reaction. ( Abebe, M; Aseffa, A; Bizuneh, E; Mulugeta, W; Shannon, EJ; Tadesse, A, 2006) |
| " Prednisolone in standard dosage schedule as recommended by WHO is now being widely used in control programmes." | 1.32 | Reactions and their management. ( Ganapati, R; Pai, VV, 2004) |
| "Treatment with thalidomide led to rapid regression." | 1.30 | [Bullous erythema nodosum leprosum. A case report in French Guiana]. ( About, V; Couppié, P; Heid, E; Pradinaud, R; Sainte-Marie, D, 1998) |
| "Thalidomide therapy was required to treat the systemic manifestations of ENL." | 1.28 | Prolonged treatment with recombinant interferon gamma induces erythema nodosum leprosum in lepromatous leprosy patients. ( Kaplan, G; Malta, AM; Moreira, AL; Sampaio, EP; Sarno, EN, 1992) |
| "We have treated three leprosy patients suffering from chronic, steroid-dependent erythema nodosum leprosum (ENL) with cyclosporine A (CsA)." | 1.27 | Treatment of chronic erythema nodosum leprosum with cyclosporine A produces clinical and immunohistologic remission. ( Harnisch, JP; Miller, RA; Rea, TH; Shen, JY, 1987) |
| "But eventually due to recurrence these cases had to be put back on steroids because of easier availability." | 1.26 | Treatment with thalidomide in steroid dependency and neuritis. ( Theophilus, S, 1980) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 33 (22.30) | 18.7374 |
| 1990's | 29 (19.59) | 18.2507 |
| 2000's | 47 (31.76) | 29.6817 |
| 2010's | 24 (16.22) | 24.3611 |
| 2020's | 15 (10.14) | 2.80 |
| Authors | Studies |
|---|---|
| Ferreira-Filho, ES | 1 |
| Bahamondes, L | 1 |
| Duarte, DC | 1 |
| Guimarães, ALM | 1 |
| de Almeida, PG | 1 |
| Soares-Júnior, JM | 1 |
| Baracat, EC | 1 |
| Sorpreso, ICE | 1 |
| Savitha, B | 1 |
| Sardana, K | 2 |
| Kumari, R | 1 |
| Khurana, A | 2 |
| Sinha, S | 1 |
| Sachdeva, S | 1 |
| Abril-Pérez, C | 1 |
| Palacios-Diaz, RD | 1 |
| Navarro-Mira, MÁ | 1 |
| Botella-Estrada, R | 1 |
| Bathula, S | 1 |
| Mathachan, SR | 1 |
| Ahuja, A | 1 |
| Paliwal, P | 1 |
| Zhou, W | 1 |
| Liu, T | 1 |
| Xiao, X | 1 |
| He, J | 1 |
| Costa, PDSS | 4 |
| Maciel-Fiuza, MF | 3 |
| Kowalski, TW | 4 |
| Fraga, LR | 4 |
| Feira, MF | 3 |
| Camargo, LMA | 3 |
| Caldoncelli, DIO | 3 |
| Silveira, MIDS | 3 |
| Schuler-Faccini, L | 5 |
| Vianna, FSL | 5 |
| Walker, SL | 2 |
| Pacheco, FS | 1 |
| Prata, RBDS | 2 |
| Brandão, SS | 2 |
| Ferreira, H | 3 |
| Rodrigues, TF | 1 |
| Brandão Dos Santos, J | 1 |
| da Silva, CO | 2 |
| Tavares, IF | 1 |
| Mendes, MA | 3 |
| Rodrigues, ACDP | 1 |
| Machado, AM | 1 |
| Nery, JADC | 1 |
| Amadeu, TP | 3 |
| Moraes, MO | 1 |
| Sarno, EN | 9 |
| Schmitz, V | 3 |
| Jesus, SM | 1 |
| Santana, RS | 2 |
| Leite, SN | 2 |
| Thangaraju, P | 1 |
| Venkatesan, S | 1 |
| Gurunthalingam, M | 1 |
| Babu, S | 1 |
| T, T | 1 |
| Sánchez-Martínez, EM | 1 |
| Melgosa-Ramos, FJ | 1 |
| Moneva-Léniz, LM | 1 |
| Gegúndez-Hernández, H | 1 |
| Prats-Máñez, A | 1 |
| Mateu-Puchades, A | 1 |
| Upputuri, B | 1 |
| Pallapati, MS | 1 |
| Tarwater, P | 1 |
| Srikantam, A | 1 |
| de Jesus, SM | 1 |
| Narang, T | 3 |
| Ashraf, R | 1 |
| Kaushik, A | 2 |
| Dogra, S | 3 |
| Chhabria, BA | 1 |
| Pannu, AK | 1 |
| Bhalla, A | 1 |
| Zhu, J | 1 |
| Yang, D | 1 |
| Shi, C | 1 |
| Jing, Z | 1 |
| de Carvalho, DS | 1 |
| Silva, BJA | 1 |
| Hacker, MA | 1 |
| Nery, JAC | 1 |
| Pinheiro, RO | 2 |
| Sampaio, EP | 6 |
| Daxbacher, ELR | 1 |
| Mehta, N | 1 |
| Ramachandran, R | 1 |
| Srikanth, S | 1 |
| Darlong, J | 1 |
| Govindharaj, P | 1 |
| Charles, DE | 1 |
| Menzies, A | 1 |
| Mani, S | 1 |
| Tavares Rodrigues, F | 1 |
| Pereira Cardozo, MR | 1 |
| da Costa Nery, JA | 1 |
| Leite, JCL | 1 |
| de Sousa, SHC | 1 |
| da Costa, LMM | 1 |
| Dias, MF | 1 |
| Morelo, EF | 1 |
| Doriqui, MJR | 1 |
| Maximino, CM | 1 |
| Sanseverino, MTV | 1 |
| Vijendran, P | 1 |
| Verma, R | 2 |
| Vasudevan, B | 2 |
| Mitra, D | 2 |
| Badad, A | 1 |
| Neema, S | 1 |
| Matsuki, T | 1 |
| Okano, Y | 2 |
| Aoki, Y | 1 |
| Ishida, Y | 2 |
| Hatano, K | 2 |
| Kumano, K | 2 |
| Pragasam, V | 1 |
| Moorchung, N | 1 |
| Gopal, M | 1 |
| Baek, MC | 1 |
| Jung, B | 1 |
| Kang, H | 1 |
| Lee, HS | 1 |
| Bae, JS | 1 |
| Leon, KE | 1 |
| Salinas, JL | 1 |
| McDonald, RW | 1 |
| Sheth, AN | 1 |
| Fairley, JK | 1 |
| Khodke, A | 1 |
| Shetty, VP | 1 |
| Petukhova, TA | 1 |
| Tartar, DM | 1 |
| Mayo, K | 1 |
| Fung, MA | 1 |
| Tuscano, J | 1 |
| Jagdeo, J | 1 |
| Prata, RB | 1 |
| Barbosa, MG | 1 |
| Rodrigues, LS | 1 |
| Costa, Fda M | 1 |
| Dos Santos, JB | 1 |
| Pacheco, Fdos S | 1 |
| Machado, Ade M | 1 |
| Nery, JA | 4 |
| Hacker, Mde A | 1 |
| Sales, AM | 2 |
| Vetrichevvel, TP | 1 |
| Pise, GA | 1 |
| Thappa, DM | 1 |
| Feuth, M | 1 |
| Brandsma, JW | 1 |
| Faber, WR | 1 |
| Bhattarai, B | 1 |
| Feuth, T | 1 |
| Anderson, AM | 1 |
| Van Veen, NH | 2 |
| Lockwood, DN | 3 |
| van Brakel, WH | 2 |
| Ramirez, J | 2 |
| Richardus, JH | 2 |
| Kaur, I | 1 |
| De, D | 1 |
| Fabi, SG | 1 |
| Hill, C | 1 |
| Witherspoon, JN | 1 |
| Boone, SL | 1 |
| West, DP | 1 |
| Vieira, JL | 1 |
| Valente, Mdo S | 1 |
| Ladizinski, B | 1 |
| Shannon, EJ | 8 |
| Sanchez, MR | 1 |
| Levis, WR | 5 |
| Ishii, N | 2 |
| Sandoval, FG | 1 |
| Morales, MJ | 2 |
| Trindade, MÂ | 1 |
| Carvalho, NB | 1 |
| Belfort, EC | 1 |
| Pagliari, C | 1 |
| Gakiya, E | 1 |
| Sakai-Valente, NY | 1 |
| Benard, G | 1 |
| Shikanai-Yasuda, MA | 1 |
| Ozaki, M | 2 |
| Gidoh, M | 1 |
| Goto, M | 1 |
| Nogami, R | 1 |
| Yamada, A | 1 |
| Yotsu, RR | 1 |
| Wan, P | 1 |
| Zhao, X | 1 |
| Hunasehally, RY | 1 |
| Shi, R | 1 |
| Zheng, J | 1 |
| Martiniuk, F | 1 |
| Giovinazzo, J | 1 |
| Tan, AU | 1 |
| Shahidullah, R | 1 |
| Haslett, P | 1 |
| Kaplan, G | 8 |
| Murthy, V | 1 |
| Horowitz, HW | 1 |
| Pham, VP | 1 |
| Wu, KL | 1 |
| Sonneveld, P | 1 |
| Teo, S | 1 |
| Resztak, KE | 1 |
| Scheffler, MA | 1 |
| Kook, KA | 2 |
| Zeldis, JB | 1 |
| Stirling, DI | 1 |
| Thomas, SD | 2 |
| Rea, TH | 4 |
| Crawford, CL | 8 |
| Okafor, MC | 1 |
| Dodd-Butera, T | 1 |
| Broderick, M | 1 |
| Perri, AJ | 1 |
| Hsu, S | 1 |
| de Carsalade, GY | 1 |
| Achirafi, A | 1 |
| Flageul, B | 1 |
| Coutsouvelis, J | 1 |
| Corallo, CE | 1 |
| Joglekar, S | 1 |
| Levin, M | 1 |
| Murakami, H | 1 |
| Sharma, NL | 3 |
| Sharma, V | 1 |
| Shanker, V | 2 |
| Mahajan, VK | 3 |
| Sarin, S | 2 |
| Ganapati, R | 1 |
| Pai, VV | 1 |
| Tadesse, A | 2 |
| Villahermosa, LG | 2 |
| Fajardo, TT | 1 |
| Abalos, RM | 2 |
| Balagon, MV | 2 |
| Tan, EV | 2 |
| Cellona, RV | 2 |
| Palmer, JP | 1 |
| Wittes, J | 1 |
| Walsh, GP | 2 |
| Walsh, DS | 1 |
| Haslett, PA | 1 |
| Roche, P | 1 |
| Butlin, CR | 1 |
| Macdonald, M | 1 |
| Shrestha, N | 1 |
| Manandhar, R | 1 |
| Lemaster, J | 1 |
| Hawksworth, R | 1 |
| Shah, M | 1 |
| Lubinsky, AS | 1 |
| Albert, M | 1 |
| Worley, J | 1 |
| Paumgartten, FJ | 1 |
| Chahoud, I | 1 |
| Naafs, B | 2 |
| Sharma, VC | 2 |
| Sharma, RC | 1 |
| Abebe, M | 1 |
| Bizuneh, E | 1 |
| Mulugeta, W | 1 |
| Aseffa, A | 1 |
| de Matos, HJ | 1 |
| Duppre, NC | 1 |
| Kawakami, T | 1 |
| Tsutsumi, Y | 1 |
| Mizoguchi, M | 1 |
| Ishi, N | 1 |
| Soma, Y | 1 |
| Ranjan, N | 1 |
| Gupta, M | 1 |
| Holzgrabe, U | 1 |
| Waters, MF | 4 |
| Esquenazi, D | 1 |
| Moreira, AL | 3 |
| Miranda, A | 2 |
| Alvarenga, FF | 1 |
| Pereira, GM | 1 |
| Paravar, T | 1 |
| Lee, DJ | 1 |
| Nielsen, H | 1 |
| Bennike, T | 1 |
| de Almeida Neto, E | 1 |
| Sheskin, J | 1 |
| Mückter, H | 1 |
| Frankus, E | 1 |
| Rajan, MA | 1 |
| Rajagopalan, MS | 1 |
| Joseph, M | 1 |
| Miranda, RO | 1 |
| Hastings, RC | 3 |
| Mshana, RN | 1 |
| Haregewoin, A | 1 |
| Belehu, A | 1 |
| Miyachi, Y | 1 |
| Uchida, K | 1 |
| Niwa, Y | 1 |
| Theophilus, S | 1 |
| dos Santos Júnior, MF | 1 |
| Lombardi, C | 1 |
| Belda, W | 1 |
| Fiallo, P | 1 |
| Pesce, C | 1 |
| Lenti, E | 1 |
| Nunzi, E | 1 |
| Gardner-Medwin, JM | 1 |
| Powell, RJ | 1 |
| Jakeman, P | 1 |
| Smith, WC | 1 |
| Miguel, CP | 1 |
| Viana, SM | 1 |
| Malta, AM | 2 |
| Vanchieri, C | 1 |
| Calderon, P | 1 |
| Anzilotti, M | 1 |
| Phelps, R | 1 |
| Fajardo, TJ | 1 |
| Partida-Sanchez, S | 1 |
| Favila-Castillo, L | 1 |
| Pedraza-Sanchez, S | 1 |
| Gomez-Melgar, M | 1 |
| Saul, A | 1 |
| Estrada-Parra, S | 1 |
| Estrada-Garcia, I | 1 |
| Nightingale, SL | 1 |
| Couppié, P | 1 |
| Sainte-Marie, D | 1 |
| About, V | 1 |
| Heid, E | 1 |
| Pradinaud, R | 1 |
| Hales, BF | 1 |
| Vides, EA | 1 |
| Cabrera, A | 1 |
| Ahern, KP | 1 |
| Keravich, DP | 1 |
| Daniels, CE | 1 |
| Marriott, JB | 1 |
| Muller, G | 1 |
| Dalgleish, AG | 1 |
| Calabrese, L | 1 |
| Fleischer, AB | 1 |
| Peuckmann, V | 1 |
| Fisch, M | 1 |
| Bruera, E | 1 |
| Clark, TE | 1 |
| Edom, N | 1 |
| Larson, J | 1 |
| Lindsey, LJ | 1 |
| Moraes, M | 1 |
| Russo, G | 1 |
| Tuinmann, G | 1 |
| Hegewisch-Becker, S | 1 |
| Hossfeld, DK | 1 |
| Petering, H | 1 |
| Kiehl, P | 1 |
| Vogelbruch, M | 1 |
| Sticht-Groh, V | 1 |
| Kapp, A | 1 |
| Werfel, T | 1 |
| Mathé, G | 1 |
| Hernandez, MO | 1 |
| Carvalho, DS | 1 |
| Levan, NE | 2 |
| Jacobson, RR | 1 |
| Trautman, JR | 2 |
| Alonso, AM | 1 |
| Awofeso, N | 1 |
| Ejigu, M | 1 |
| Haile-Mariam, HS | 1 |
| Berhan, TY | 1 |
| Tasesse, G | 1 |
| Hooper, M | 1 |
| Jew, LJ | 1 |
| Middleton, RK | 1 |
| Randall, T | 1 |
| Salafia, A | 1 |
| Kharkar, RD | 1 |
| Bullock, WE | 1 |
| Bourdillon, C | 1 |
| Schuller-Levis, G | 1 |
| Harris, D | 1 |
| Cutler, E | 1 |
| Meeker, HC | 1 |
| Haubenstock, H | 1 |
| Miller, RA | 1 |
| Shen, JY | 1 |
| Harnisch, JP | 1 |
| Viraben, R | 1 |
| Dupré, A | 1 |
| Gad, SM | 1 |
| Krotoski, WA | 1 |
| Moncada, B | 1 |
| Baranda, ML | 1 |
| González-Amaro, R | 1 |
| Urbina, R | 1 |
| Loredo, CE | 1 |
| Levy, L | 1 |
| Fasal, P | 1 |
| Freedman, RI | 1 |
| Swift, TR | 1 |
| Pearson, JM | 2 |
| Vedagiri, M | 1 |
| Opromolla, DV | 1 |
| Lima, LS | 1 |
| Marques, MB | 1 |
| Nelson, DS | 1 |
| Nelson, M | 1 |
| Thurston, JM | 1 |
| Languillon, J | 1 |
| Klein, JM | 1 |
| Giraudeau, P | 1 |
| Baccaredda-Boy, A | 1 |
| Bertamino, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Pilot Study to Evaluate the Efficacy and Safety of Apremilast in Patients of Chronic and Recurrent Erythema Nodosum Leprosum[NCT04822909] | Phase 4 | 10 participants (Actual) | Interventional | 2019-09-15 | Completed | ||
| Methotrexate and Prednisolone Study in Erythema Nodosum Leprosum (MaPS in ENL[NCT03775460] | 550 participants (Anticipated) | Interventional | 2023-01-15 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
33 reviews available for thalidomide and Erythema Nodosum
| Article | Year |
|---|---|
The organization, weaknesses, and challenges of the control of thalidomide in Brazil: A review.
Topics: Abnormalities, Drug-Induced; Brazil; Erythema Nodosum; Female; Humans; Leprostatic Agents; Leprosy; | 2020 |
Comparative analysis of the use and control of thalidomide in Brazil and different countries: is it possible to say there is safety?
Topics: Brazil; Drug Monitoring; Erythema Nodosum; Female; Humans; Leprostatic Agents; Leprosy; Leprosy, Lep | 2022 |
Erythema Nodosum Leprosum: Update and challenges on the treatment of a neglected condition.
Topics: Anti-Inflammatory Agents; Erythema Nodosum; Glucocorticoids; Humans; Inflammation; Leprostatic Agent | 2018 |
Recognition of the phenotype of thalidomide embryopathy in countries endemic for leprosy: new cases and review of the main dysmorphological findings.
Topics: Brazil; Endemic Diseases; Erythema Nodosum; Female; Fetal Diseases; Humans; Hypnotics and Sedatives; | 2013 |
Novel insight into drug repositioning: Methylthiouracil as a case in point.
Topics: Animals; Anti-Inflammatory Agents; Antithyroid Agents; Arthritis, Rheumatoid; Biomarkers; Doxycyclin | 2015 |
Interventions for erythema nodosum leprosum.
Topics: Aspirin; Clofazimine; Erythema Nodosum; Humans; Leprostatic Agents; Leprosy, Lepromatous; Prednisolo | 2009 |
Frequency of thromboembolic events associated with thalidomide in the non-cancer setting: a case report and review of the literature.
Topics: Adult; Drug Therapy, Combination; Erythema Nodosum; Humans; Leprostatic Agents; Leprosy, Lepromatous | 2009 |
Interventions for erythema nodosum leprosum. A Cochrane review.
Topics: Aspirin; Clofazimine; Erythema Nodosum; Humans; Leprostatic Agents; Leprosy, Lepromatous; Prednisolo | 2009 |
Thalidomide and analogues: potential for immunomodulation of inflammatory and neoplastic dermatologic disorders.
Topics: Behcet Syndrome; Dermatitis; Erythema Nodosum; Humans; Immunomodulation; Lupus Erythematosus, Cutane | 2010 |
A patient with erythema nodosus leprosum and Chagas cardiopathy: challenges in patient management and review of the literature.
Topics: Adrenal Cortex Hormones; Brazil; Chagas Cardiomyopathy; Erythema Nodosum; Female; Heart Diseases; Hu | 2011 |
[Japanese guideline on thalidomide usage in the management of erythema nodosum leprosum].
Topics: Erythema Nodosum; Humans; Japan; Leprostatic Agents; Leprosy, Lepromatous; Practice Guidelines as To | 2011 |
[Thalidomide: new uses for an old drug].
Topics: Angiogenesis Inhibitors; Drug Approval; Erythema Nodosum; Graft vs Host Disease; Humans; Immune Syst | 2002 |
Thalidomide in the treatment of leprosy.
Topics: Drug Therapy, Combination; Erythema Nodosum; Humans; Incidence; Leprostatic Agents; Leprosy; Leprosy | 2002 |
Thalidomide for erythema nodosum leprosum and other applications.
Topics: Animals; Cachexia; Erythema Nodosum; Graft vs Host Disease; Humans; Leprosy, Lepromatous; Multiple M | 2003 |
A review of thalidomide's history and current dermatological applications.
Topics: Dermatologic Agents; Erythema Nodosum; History, 20th Century; History, 21st Century; Humans; Leprosy | 2003 |
The promise of thalidomide: evolving indications.
Topics: Cachexia; Carcinoma, Renal Cell; Clinical Trials as Topic; Erythema Nodosum; Graft vs Host Disease; | 2004 |
[New pharmacological availability of thalidomide based on experience in patients with multiple myeloma].
Topics: Animals; Blood Vessels; Clinical Trials, Phase II as Topic; Ectromelia; Erythema Nodosum; Female; Hu | 2004 |
Treatment of leprosy: science or politics?
Topics: Attitude to Health; Erythema Nodosum; Health Knowledge, Attitudes, Practice; Health Policy; Humans; | 2006 |
[An old drug as a carcinostatic. The new career of thalidomide].
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Erythema Nodosum; Humans; Immunologic Factors; Multi | 2007 |
The role of thalidomide in the management of erythema nodosum leprosum.
Topics: Aspirin; Controlled Clinical Trials as Topic; Decision Trees; Erythema Nodosum; Humans; Leprostatic | 2007 |
Thalidomide: mechanisms of action.
Topics: Angiogenesis Inhibitors; Erythema Nodosum; Humans; Immune System; Immunity, Active; Immunity, Innate | 2008 |
Use of thalidomide in leprosy.
Topics: Erythema Nodosum; Humans; Leprosy; Nervous System Diseases; Peripheral Nervous System; Thalidomide | 1994 |
Bangkok Workshop on Leprosy Research. Treatment of reactions and nerve damage.
Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Clofazimine; Cyclosporine; Drug A | 1996 |
Thalidomide in dermatology. New indications for an old drug.
Topics: Abnormalities, Drug-Induced; Erythema Nodosum; History, 20th Century; Humans; Immunosuppressive Agen | 1997 |
Thalidomide as an emerging immunotherapeutic agent.
Topics: Abnormalities, Drug-Induced; Acquired Immunodeficiency Syndrome; Adjuvants, Immunologic; Anti-Inflam | 1999 |
Thalidomide: current and potential clinical applications.
Topics: Angiogenesis Inhibitors; Anti-HIV Agents; Arthritis, Rheumatoid; Behcet Syndrome; Dermatologic Agent | 2000 |
Potential novel uses of thalidomide: focus on palliative care.
Topics: Angiogenesis Inhibitors; Animals; Cachexia; Cytokines; Erythema Nodosum; Graft vs Host Disease; Huma | 2000 |
Potential of thalidomide and thalidomide analogues as immunomodulatory drugs in leprosy and leprosy reactions.
Topics: Erythema Nodosum; Female; Humans; Immunosuppressive Agents; Leprosy, Lepromatous; Male; Prognosis; T | 2000 |
Thalomid (Thalidomide) capsules: a review of the first 18 months of spontaneous postmarketing adverse event surveillance, including off-label prescribing.
Topics: Angiogenesis Inhibitors; Anti-HIV Agents; Drug Labeling; Erythema Nodosum; Female; Hallucinations; H | 2001 |
Thalidomide and its dermatologic uses.
Topics: Acquired Immunodeficiency Syndrome; Behcet Syndrome; Dermatologic Agents; Erythema Nodosum; Facial D | 2001 |
[New indications for thalidomide?].
Topics: Abnormalities, Drug-Induced; Adolescent; Adult; Angiogenesis Inhibitors; Animals; Anti-HIV Agents; A | 2001 |
Management of erythema nodosum leprosum by thalidomide: thalidomide analogues inhibit M. leprae-induced TNFalpha production in vitro.
Topics: Apoptosis; Cytokines; Erythema Nodosum; Humans; Immunosuppressive Agents; Interleukin-12; Monocytes; | 2002 |
Thalidomide in erythema nodosum leprosum.
Topics: Erythema Nodosum; Humans; Leprosy, Lepromatous; Thalidomide | 1990 |
14 trials available for thalidomide and Erythema Nodosum
| Article | Year |
|---|---|
Erythema nodosum leprosum in Nepal: a retrospective study of clinical features and response to treatment with prednisolone or thalidomide.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents; Child; Erythema Nodosum; Female; Humans; Leprosta | 2008 |
Comparative efficacy of thalidomide and prednisolone in the treatment of moderate to severe erythema nodosum leprosum: a randomized study.
Topics: Administration, Oral; Adult; Dose-Response Relationship, Drug; Drug Administration Schedule; Erythem | 2009 |
[Pentoxifylline in the treatment of erythema nodosum leprosum: results of an open study].
Topics: Adolescent; Adult; Erythema Nodosum; Female; Follow-Up Studies; Glucocorticoids; Humans; Immunosuppr | 2003 |
A randomized, double-blind, double-dummy, controlled dose comparison of thalidomide for treatment of erythema nodosum leprosum.
Topics: Adolescent; Adult; Dose-Response Relationship, Drug; Double-Blind Method; Erythema Nodosum; Humans; | 2005 |
Double-blind trial of the efficacy of pentoxifylline vs thalidomide for the treatment of type II reaction in leprosy.
Topics: Adolescent; Adult; Double-Blind Method; Erythema Nodosum; Female; Humans; Leprostatic Agents; Lepros | 2007 |
Thalidomide: an experience in therapeutic outcome and adverse reactions.
Topics: Adult; Anti-Inflammatory Agents; Behcet Syndrome; Erythema Nodosum; Female; Humans; Leprosy; Lichen | 2007 |
[Comparative study of the therapeutic activity of glutamic acid phthalimide and the therapeutic activity of triamcinolone in the treatment of Hansen's reaction of Virchowian Leprosy].
Topics: Clinical Trials as Topic; Double-Blind Method; Erythema Nodosum; Humans; Leprosy; Thalidomide; Triam | 1981 |
Cytokine regulation of disease progression in leprosy and tuberculosis.
Topics: AIDS-Related Opportunistic Infections; Cytokines; Erythema Nodosum; HIV-1; Humans; Immunity, Cellula | 1994 |
Effect of rhuIFN-gamma treatment in multibacillary leprosy patients.
Topics: Clofazimine; Dapsone; Drug Therapy, Combination; Erythema Nodosum; Humans; Interferon-gamma; Leprost | 1996 |
IgG antibody subclasses, tumor necrosis factor and IFN-gamma levels in patients with type II lepra reaction on thalidomide treatment.
Topics: Adolescent; Adult; Aged; Antibodies, Bacterial; Data Interpretation, Statistical; Erythema Nodosum; | 1998 |
Effect of zafirlukast on leprosy reactions.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Clofazimine; Cohort Studies; D | 1999 |
An internally-controlled double blind trial of thalidomide in severe erythema nodosum leprosum.
Topics: Adrenocorticotropic Hormone; Adult; Chronic Disease; Clinical Trials as Topic; Erythema Nodosum; Hum | 1971 |
Treatment of moderately severe erythema nodosum leprosum with thalidomide--a double-blind controlled trial.
Topics: Clinical Trials as Topic; Erythema Nodosum; Female; Humans; Leprosy; Male; Placebos; Thalidomide | 1969 |
[Thalidomide in acute symptoms in leprosy (erythema nodosum or multiforme)].
Topics: Clinical Trials as Topic; Erythema Multiforme; Erythema Nodosum; Female; Humans; Lepromin; Leprosy; | 1966 |
101 other studies available for thalidomide and Erythema Nodosum
| Article | Year |
|---|---|
Etonogestrel-releasing contraceptive implant in a patient using thalidomide for the treatment of erythema nodosum leprosum: a case report.
Topics: Adult; Contraceptive Agents, Female; Desogestrel; Drug Implants; Drug Interactions; Erythema Nodosum | 2022 |
Case Report: Rapid Response to Low-Dose Thalidomide in a Case of Severe Steroid Recalcitrant Erythema Nodosum Leprosum.
Topics: Adult; Diagnosis, Differential; Erythema Nodosum; Female; Humans; Leprostatic Agents; Leprosy, Lepro | 2021 |
Successful treatment of erythema nodosum leprosum with apremilast.
Topics: Erythema Nodosum; Humans; Leprosy, Lepromatous; Leprosy, Multibacillary; Panniculitis; Thalidomide | 2022 |
A real-world study of low-dose thalidomide in severe erythema nodosum leprosum highlighting its mechanistic rationale in a resource-constrained target population.
Topics: Erythema Nodosum; Humans; Leprostatic Agents; Leprosy, Lepromatous; Leprosy, Multibacillary; Pannicu | 2023 |
Refractory Behçet's disease treated with low-dose interleukin-2: A case report.
Topics: Adult; Behcet Syndrome; Erythema Nodosum; Female; Humans; Hydroxychloroquine; Interleukin-2; Methylp | 2022 |
Evaluation of the influence of genetic variants in Cereblon gene on the response to the treatment of erythema nodosum leprosum with thalidomide.
Topics: Erythema Nodosum; Humans; Leprostatic Agents; Leprosy, Lepromatous; Leprosy, Multibacillary; Thalido | 2022 |
Evaluation of the influence of genetic variants in Cereblon gene on the response to the treatment of erythema nodosum leprosum with thalidomide.
Topics: Erythema Nodosum; Humans; Leprostatic Agents; Leprosy, Lepromatous; Leprosy, Multibacillary; Thalido | 2022 |
Evaluation of the influence of genetic variants in Cereblon gene on the response to the treatment of erythema nodosum leprosum with thalidomide.
Topics: Erythema Nodosum; Humans; Leprostatic Agents; Leprosy, Lepromatous; Leprosy, Multibacillary; Thalido | 2022 |
Evaluation of the influence of genetic variants in Cereblon gene on the response to the treatment of erythema nodosum leprosum with thalidomide.
Topics: Erythema Nodosum; Humans; Leprostatic Agents; Leprosy, Lepromatous; Leprosy, Multibacillary; Thalido | 2022 |
Evaluation of the influence of genetic variants in Cereblon gene on the response to the treatment of erythema nodosum leprosum with thalidomide.
Topics: Erythema Nodosum; Humans; Leprostatic Agents; Leprosy, Lepromatous; Leprosy, Multibacillary; Thalido | 2022 |
Evaluation of the influence of genetic variants in Cereblon gene on the response to the treatment of erythema nodosum leprosum with thalidomide.
Topics: Erythema Nodosum; Humans; Leprostatic Agents; Leprosy, Lepromatous; Leprosy, Multibacillary; Thalido | 2022 |
Evaluation of the influence of genetic variants in Cereblon gene on the response to the treatment of erythema nodosum leprosum with thalidomide.
Topics: Erythema Nodosum; Humans; Leprostatic Agents; Leprosy, Lepromatous; Leprosy, Multibacillary; Thalido | 2022 |
Evaluation of the influence of genetic variants in Cereblon gene on the response to the treatment of erythema nodosum leprosum with thalidomide.
Topics: Erythema Nodosum; Humans; Leprostatic Agents; Leprosy, Lepromatous; Leprosy, Multibacillary; Thalido | 2022 |
Evaluation of the influence of genetic variants in Cereblon gene on the response to the treatment of erythema nodosum leprosum with thalidomide.
Topics: Erythema Nodosum; Humans; Leprostatic Agents; Leprosy, Lepromatous; Leprosy, Multibacillary; Thalido | 2022 |
New therapeutics for leprosy.
Topics: Erythema Nodosum; Humans; Leprosy; Thalidomide | 2020 |
Erythema Nodosum Leprosum Neutrophil Subset Expressing IL-10R1 Transmigrates into Skin Lesions and Responds to IL-10.
Topics: Adult; Cells, Cultured; Cytokines; Erythema Nodosum; Female; Humans; Inflammation Mediators; Interle | 2020 |
Rationale use of Thalidomide in erythema nodosum leprosum - A non-systematic critical analysis of published case reports.
Topics: Adolescent; Adult; Aged; Child; Child, Preschool; Erythema Nodosum; Female; Humans; Infant; Leprosta | 2020 |
Erythema nodosum leprosum successfully treated with apremilast: more effective and safer than classic treatments?
Topics: Erythema Nodosum; Humans; Leprosy, Lepromatous; Leprosy, Multibacillary; Thalidomide | 2021 |
Thalidomide in the treatment of erythema nodosum leprosum (ENL) in an outpatient setting: A five-year retrospective analysis from a leprosy referral centre in India.
Topics: Adult; Erythema Nodosum; Female; Humans; India; Leprostatic Agents; Leprosy, Lepromatous; Male; Midd | 2020 |
Apremilast in multibacillary leprosy patients with chronic and recurrent erythema nodosum leprosum: a prospective single-centre pilot study.
Topics: Erythema Nodosum; Humans; Leprosy, Lepromatous; Leprosy, Multibacillary; Pilot Projects; Prospective | 2021 |
Venous thrombo-embolism: thalidomide and leprosy.
Topics: Computed Tomography Angiography; Electrocardiography; Erythema Nodosum; Humans; Leprosy, Lepromatous | 2017 |
Therapeutic Dilemma of Refractory Erythema Nodosum Leprosum.
Topics: Adrenal Cortex Hormones; Drug Tolerance; Erythema Nodosum; Fatal Outcome; Humans; Immunosuppressive | 2017 |
Elevated Pentraxin-3 Concentrations in Patients With Leprosy: Potential Biomarker of Erythema Nodosum Leprosum.
Topics: Adolescent; Adult; Aged; Biomarkers; C-Reactive Protein; Case-Control Studies; Child; Enzyme-Linked | 2017 |
Erythema Necroticans - A Case Report.
Topics: Adult; Erythema Nodosum; Humans; Leprosy, Lepromatous; Male; Neutrophils; Thalidomide | 2016 |
Experiences with Thalidomide for Erythema Nodosum Leprosum– a retrospective study.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Erythema Nodosum; Female; Humans; Leprosy, Lepromatous; | 2016 |
Widespread Dermatophytosis in a Patient Treated for Leprosy Type II Reactional State after MDT/WHO-MB Release.
Topics: Antifungal Agents; Brazil; Dapsone; Erythema Nodosum; Humans; Leprostatic Agents; Leprosy, Lepromato | 2018 |
Apremilast in chronic recalcitrant erythema nodosum leprosum: a report of two cases.
Topics: Erythema Nodosum; Humans; Leprosy, Lepromatous; Leprosy, Multibacillary; Thalidomide | 2020 |
Rare atypical presentations in Type 2 lepra reaction: a case series.
Topics: Adult; Erythema Nodosum; Female; Humans; Immune Complex Diseases; Leprostatic Agents; Leprosy, Lepro | 2014 |
[Effectiveness of thalidomide for erythema nodosum leprosum (ENL): retrospective study of 20 Japanese cases in National Sanatrium Oku-Komyoen].
Topics: Adult; Aged; Asian People; Drug Administration Schedule; Erythema Nodosum; Female; Humans; Japan; Le | 2014 |
Bullous erythema nodosum leprosum manifesting in the post partum period with unusual features.
Topics: Adult; Erythema Nodosum; Female; Humans; Leprostatic Agents; Leprosy, Borderline; Leprosy, Lepromato | 2015 |
Complex Type 2 Reactions in Three Patients with Hansen's Disease from a Southern United States Clinic.
Topics: Adult; Aged; Anti-Inflammatory Agents; Asia, Southeastern; Bangladesh; Erythema Nodosum; Female; Geo | 2015 |
Type 1 reaction masquerading clinically as ENL: A Case Report.
Topics: Adult; Erythema Nodosum; Humans; Leprostatic Agents; Leprosy, Lepromatous; Male; Thalidomide | 2015 |
Erythema Nodosum-like Septal Panniculitis Secondary to Lenalidomide Therapy in a Patient With Janus Kinase 2-Positive Myelofibrosis.
Topics: Aged; Erythema Nodosum; Humans; Immunologic Factors; Janus Kinase 2; Lenalidomide; Male; Panniculiti | 2016 |
Expression of CD64 on Circulating Neutrophils Favoring Systemic Inflammatory Status in Erythema Nodosum Leprosum.
Topics: Adolescent; Adult; Aged; Biopsy; Erythema Nodosum; Female; Humans; Leprostatic Agents; Leprosy, Bord | 2016 |
A case report of venous thrombosis in a leprosy patient treated with corticosteroid and thalidomide.
Topics: Adrenal Cortex Hormones; Adult; Erythema Nodosum; Humans; Leprosy, Lepromatous; Male; Thalidomide; V | 2008 |
Thalidomide levels in patients with erythema nodosum leprosum.
Topics: Adult; Chromatography, Liquid; Erythema Nodosum; Humans; Leprostatic Agents; Leprosy, Lepromatous; M | 2009 |
[Thalidomide--coverage by health insurance when used for treatment of ENL].
Topics: Adult; Aged; Drug Utilization; Drug-Related Side Effects and Adverse Reactions; Erythema Nodosum; Fe | 2010 |
In vitro thalidomide does not interfere with the activation of complement by M. leprae.
Topics: Animals; Complement Activation; Complement System Proteins; Erythema Nodosum; Humans; Leprostatic Ag | 2011 |
Propylthiouracil-induced ANCA-positive erythema nodosum treated with thalidomide.
Topics: Antibodies, Antineutrophil Cytoplasmic; Antithyroid Agents; Erythema Nodosum; Female; Humans; Hypert | 2012 |
Lessons of leprosy: the emergence of TH17 cytokines during type II reactions (ENL) is teaching us about T-cell plasticity.
Topics: Adolescent; Adult; Biopsy; Cytokines; Erythema Nodosum; Gene Expression Regulation; Humans; Interleu | 2012 |
Giant PPD reaction with positive QuantiFERON-TB Gold in a patient with lepromatous leprosy.
Topics: Adult; Erythema Nodosum; Humans; Interferon-gamma Release Tests; Latent Tuberculosis; Leprosy, Lepro | 2012 |
Elevated platelet counts and thrombocytosis in erythema nodosum leprosum.
Topics: Adult; Erythema Nodosum; Female; Humans; Leprostatic Agents; Leprosy, Lepromatous; Male; Mexico; Mid | 2002 |
The schizophrenic career of a "monster drug".
Topics: Dapsone; Erythema Nodosum; Humans; Leprostatic Agents; Leprosy; Leprosy, Lepromatous; Nervous System | 2003 |
Thalidomide makes a comeback.
Topics: Abnormalities, Drug-Induced; Angiogenesis Inhibitors; Ectromelia; Erythema Nodosum; Female; Humans; | 2003 |
Licensing thalidomide in Australia.
Topics: Australia; Drug and Narcotic Control; Erythema Nodosum; Humans; Leprosy, Lepromatous; Thalidomide | 2004 |
Thalidomide-induced bradycardia and its management.
Topics: Aged; Bradycardia; Dose-Response Relationship, Drug; Drug Administration Schedule; Electrocardiograp | 2004 |
Does thalidomide have a role in leprosy?
Topics: Erythema Nodosum; Humans; Leprostatic Agents; Leprosy, Lepromatous; Thalidomide | 2004 |
Deep vein thrombosis: a rare complication of thalidomide therapy in recurrent erythema nodosum leprosum.
Topics: Adult; Cyclophosphamide; Dexamethasone; Drug Therapy, Combination; Erythema Nodosum; Female; Glucoco | 2004 |
Reactions and their management.
Topics: Arthritis; Cicatrix; Clofazimine; Dose-Response Relationship, Drug; Drug-Related Side Effects and Ad | 2004 |
Concerns regarding in vitro and in vivo uses of thalidomide.
Topics: Erythema Nodosum; Humans; Leprostatic Agents; Leprosy, Lepromatous; Thalidomide | 2005 |
Effective treatment of erythema nodosum leprosum with thalidomide is associated with immune stimulation.
Topics: Adolescent; Adult; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cytokines; Erythema Nodos | 2005 |
Thalidomide embryopathy cases in Brazil after 1965.
Topics: Adult; Brazil; Drug Utilization Review; Erythema Nodosum; Female; Fetal Diseases; Humans; Leprosy, L | 2006 |
No role for thalidomide in the treatment of leprosy.
Topics: Erythema Nodosum; Humans; Leprostatic Agents; Leprosy, Lepromatous; Thalidomide | 2006 |
Erythema nodosum leprosum and HIV infection: A therapeutic experience.
Topics: Adult; Anti-HIV Agents; Colchicine; Erythema Nodosum; HIV Infections; Humans; Ibuprofen; Leprostatic | 2005 |
Effect of thalidomide on the expression of TNF-alpha m-RNA and synthesis of TNF-alpha in cells from leprosy patients with reversal reaction.
Topics: Adolescent; Adult; Aged; Antigens, Bacterial; Cell Proliferation; Cell Survival; Cells, Cultured; Er | 2006 |
Clinicopathologic challenge.
Topics: Adult; Diagnosis, Differential; Erythema Nodosum; Extremities; Facial Dermatoses; Female; Humans; Le | 2007 |
Clinical, immunological and histological aspects of an uncommon type II reaction in patients with lepromatous leprosy.
Topics: Aged; Antiviral Agents; Erythema Nodosum; Humans; Interferon-gamma; Leprosy, Lepromatous; Male; Midd | 2008 |
Thalidomide enhances defective monocyte function in lepromatous leprosy.
Topics: Adult; Erythema Nodosum; Humans; Leprosy; Male; Monocytes; Thalidomide | 1984 |
[Supidimide, a non-teratogenic thalidomide analog for the treatment of leprosy reaction?].
Topics: Adult; Drug Therapy, Combination; Erythema Nodosum; Female; Humans; Leprostatic Agents; Leprosy; Mal | 1983 |
A clinical study of thalidomide comparing pre-treatment and post-treatment reactional episodes and corticosteroid requirements.
Topics: Adolescent; Drug Therapy, Combination; Erythema Nodosum; Humans; Leprosy; Male; Prednisolone; Thalid | 1983 |
Inhibition of de novo IgM antibody synthesis by thalidomide as a relevant mechanism of action in leprosy.
Topics: Animals; Complement C3; Erythema Nodosum; Female; Hemagglutinins; Hemolytic Plaque Technique; Immuno | 1981 |
Thymus-dependent lymphocytes in leprosy. II. Effect of chemotherapy on T-lymphocyte subpopulations.
Topics: Antibodies, Monoclonal; Dapsone; Erythema Nodosum; Humans; Leprosy; Lymphocyte Activation; Mycobacte | 1982 |
Effects of thalidomide on the generation of oxygen intermediates by zymosan-stimulated normal polymorphonuclear leukocytes.
Topics: Cells, Cultured; Depression, Chemical; Erythema Nodosum; Humans; Hydrogen Peroxide; Hydroxides; Lepr | 1982 |
Treatment with thalidomide in steroid dependency and neuritis.
Topics: Adrenal Cortex Hormones; Erythema Nodosum; Humans; Leprosy; Male; Neuritis; Recurrence; Thalidomide | 1980 |
[Thalidomide: a review of the literature].
Topics: Animals; Chemical Phenomena; Chemistry; Erythema Nodosum; Humans; Leprosy; Rats; Skin Diseases; Tera | 1981 |
Kellersberger Memorial Lecture 1979: immunosuppressive/anti-inflammatory thalidomide analogues.
Topics: Animals; Anti-Inflammatory Agents; Erythema Nodosum; Immunosuppressive Agents; Leprosy; Mice; Rats; | 1980 |
Short report: erythema nodosum leprosum lymphadenitis.
Topics: Erythema Nodosum; Humans; Leprosy, Lepromatous; Lymph Nodes; Lymphadenitis; Male; Middle Aged; Thali | 1995 |
Thalidomide--the way forward.
Topics: Abnormalities, Drug-Induced; Erythema Nodosum; Humans; Leprosy, Lepromatous; Thalidomide | 1994 |
Thalidomide in leprosy reaction.
Topics: Erythema Nodosum; Female; Humans; Leprosy, Lepromatous; Pregnancy; Thalidomide | 1994 |
The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum.
Topics: Adult; Erythema Nodosum; Female; Humans; Leprosy, Lepromatous; Male; Middle Aged; Thalidomide; Tumor | 1993 |
New uses of thalidomide.
Topics: Erythema Nodosum; Humans; Stomatitis, Aphthous; Thalidomide | 1996 |
Preparing for thalidomide's comeback.
Topics: Drug Approval; Erythema Nodosum; Female; Humans; Leprostatic Agents; Leprosy, Lepromatous; Male; Tha | 1997 |
Comparison of pentoxifylline, thalidomide and prednisone in the treatment of ENL.
Topics: Adolescent; Adult; Cytokines; Erythema Nodosum; Female; Humans; Leprosy, Lepromatous; Male; Pentoxif | 1998 |
From the Food and Drug Administration.
Topics: Drug Approval; Erythema Nodosum; Humans; Leprostatic Agents; Leprosy, Lepromatous; Policy Making; Th | 1998 |
[Bullous erythema nodosum leprosum. A case report in French Guiana].
Topics: Adult; Diagnosis, Differential; Erythema Nodosum; French Guiana; Humans; Leprostatic Agents; Leprosy | 1998 |
Thalidomide on the comeback trail.
Topics: Adjuvants, Immunologic; Animals; DNA; Drug Approval; Erythema Nodosum; Female; Free Radicals; Matern | 1999 |
Challenges of thalidomide distribution in a hospital setting.
Topics: Anti-Infective Agents; Drug Prescriptions; Erythema Nodosum; Female; Guidelines as Topic; Humans; Im | 1999 |
Thalidomide: new preparation. For well-defined indications.
Topics: Behcet Syndrome; Clinical Trials as Topic; Erythema Nodosum; France; Graft vs Host Disease; Humans; | 1998 |
[Chemotherapy-induced erythema nodosum leprosum: successful treatment with thalidomide].
Topics: Adult; Dapsone; Dermatologic Agents; Drug Therapy, Combination; Erythema Nodosum; Follow-Up Studies; | 2001 |
Thalidomide, a drug which may protect the organism against some aggressive effects of the immunologic system.
Topics: Acquired Immunodeficiency Syndrome; Erythema Nodosum; Graft vs Host Reaction; Humans; Immunosuppress | 2002 |
24th Kellersberger Memorial lecture, 1999 thalidomide: will the past overshadow a promising future?
Topics: Erythema Nodosum; Humans; Immunity, Cellular; Leprostatic Agents; Leprosy, Lepromatous; T-Lymphocyte | 1999 |
Decreases in mean hemoglobin and serum albumin values in erythema nodosum leprosum and lepromatous leprosy.
Topics: Anemia; Dapsone; Erythema Nodosum; Hemoglobins; Humans; Leprostatic Agents; Leprosy, Lepromatous; Pr | 2001 |
Lucio's phenomenon and diffuse nonnodular lepromatous leprosy.
Topics: Adult; Dapsone; Erythema Nodosum; Female; Humans; Ischemia; Leprosy; Lymphopenia; Male; Middle Aged; | 1978 |
The diagnosis and treatment of leprosy.
Topics: Biopsy; Clofazimine; Dapsone; Erythema Nodosum; Humans; Immunotherapy; Leprosy; Recurrence; Rifampin | 1976 |
Treatment of Hansen's disease.
Topics: Chloroquine; Clofazimine; Dapsone; Drug Resistance, Microbial; Erythema Nodosum; Humans; Leprosy; Pr | 1976 |
[Reactional status of leprosy].
Topics: Erythema Multiforme; Erythema Nodosum; Humans; Thalidomide; Tuberculoma | 1975 |
Thalidomide peripheral neuropathy.
Topics: Erythema Nodosum; Humans; Leprosy, Lepromatous; Male; Nigeria; Peripheral Nervous System Diseases; T | 1992 |
Thalidomide's effectiveness in erythema nodosum leprosum is associated with a decrease in CD4+ cells in the peripheral blood.
Topics: Adult; CD4-CD8 Ratio; Erythema Nodosum; Humans; Leprosy, Lepromatous; Male; Thalidomide | 1992 |
Prolonged treatment with recombinant interferon gamma induces erythema nodosum leprosum in lepromatous leprosy patients.
Topics: Erythema Nodosum; Humans; Interferon-gamma; Leprosy, Borderline; Leprosy, Lepromatous; Monocytes; Re | 1992 |
Use of thalidomide in leprosy.
Topics: Erythema Nodosum; Humans; Leprosy, Lepromatous; Peripheral Nervous System Diseases; Thalidomide | 1991 |
Use of thalidomide in leprosy.
Topics: Erythema Nodosum; Humans; Leprosy, Lepromatous; Thalidomide | 1991 |
Use of thalidomide in leprosy.
Topics: Erythema Nodosum; Humans; Leprosy, Lepromatous; Thalidomide | 1991 |
Investigational new drug (US) 'orphan' trials now use thalidomide from two sources.
Topics: Drug Industry; Erythema Nodosum; Graft vs Host Disease; Leprosy, Lepromatous; Orphan Drug Production | 1990 |
Thalidomide and exfoliative dermatitis.
Topics: Drug Eruptions; Erythema Nodosum; Humans; Leprosy, Lepromatous; Male; Middle Aged; Thalidomide | 1988 |
The clinical significance of erythema nodosum.
Topics: Adult; Anti-Inflammatory Agents; Antigen-Antibody Complex; Coccidioidomycosis; Diagnosis, Differenti | 1986 |
Thalidomide in erythema nodosum leprosum (ENL)
Topics: Adult; Erythema Nodosum; Humans; Leprosy, Lepromatous; Male; Thalidomide | 1988 |
Defective monocyte chemotaxis in active lepromatous leprosy.
Topics: Antibodies, Bacterial; Antigens, Bacterial; Chemotaxis, Leukocyte; Erythema Nodosum; Glycolipids; Hu | 1987 |
Treatment of chronic erythema nodosum leprosum with cyclosporine A produces clinical and immunohistologic remission.
Topics: Adult; Antibodies, Bacterial; Antigen-Antibody Complex; Chronic Disease; Cyclosporins; Erythema Nodo | 1987 |
Erythema nodosum following thalidomide therapy for Behçet's disease.
Topics: Adult; Behcet Syndrome; Erythema Nodosum; Humans; Male; Thalidomide | 1988 |
Thalidomide induces imbalances in T-lymphocyte sub-populations in the circulating blood of healthy males.
Topics: Adult; Erythema Nodosum; Humans; Leprosy; Leukocyte Count; Middle Aged; T-Lymphocytes; Thalidomide | 1985 |
Thalidomide--effect on T cell subsets as a possible mechanism of action.
Topics: Adolescent; Behcet Syndrome; Erythema Nodosum; Female; Humans; Leprosy; T-Lymphocytes; Thalidomide | 1985 |
Mechanisms of reactions in leprosy.
Topics: Acute Disease; Adrenal Cortex Hormones; Animals; Antibody Formation; Chronic Disease; Erythema Nodos | 1972 |
Treatment of erythema nodosum leprosum with thalidomide.
Topics: Acute Disease; Adrenal Cortex Hormones; Adult; Erythema Nodosum; Female; Humans; Leprosy; Male; Recu | 1973 |
Treatment of erythema nodosum leprosum with thalidomide.
Topics: Axons; Biopsy; Erythema Nodosum; Humans; Leprosy; Peripheral Nervous System Diseases; Thalidomide | 1973 |
Letter: Thalidomide in erythema nodosum leprosum.
Topics: Erythema Nodosum; Humans; Leprosy; Thalidomide | 1973 |
Letter: Thalidomide in erythema nodosum leprosum.
Topics: Erythema Nodosum; Humans; Leprosy; Thalidomide | 1973 |
Phytohaemagglutinin-induced lymphocyte transformation in leprosy.
Topics: Asian People; Biopsy; China; Erythema Nodosum; Humans; India; Lectins; Leprosy; Lymphocyte Activatio | 1971 |
[Treatment of leprous reaction of the erythema nodosum type with thalidomide (N-phthalimidoglutarimide)].
Topics: Ectromelia; Erythema Nodosum; Female; Humans; Leprosy; Male; Pregnancy; Sex Factors; Thalidomide | 1968 |
[Our experience in the therapy of leprous reactions with thalidomide].
Topics: Erythema Multiforme; Erythema Nodosum; Humans; Leprosy; Thalidomide | 1968 |